Cgabryszek: Created page with "'''Class''' Antiarrhythmic agent '''Pharmacology and Actions''' # Suppresses ventricular ectopy and increases ventricular fibrillation threshold. # Noncompetitive blocker of alpha and beta adrenergic receptors which can cause: ## Negative chronotropic effects ## Negative inotropic effects (the effect on cardiac output by the negative inotropic effect is balanced by a decrease in afterload and increase in coronary blood flow, which in turn improves cardiac performance..."

2022-04-04T03:18:37Z

Created page with "'''Class''' Antiarrhythmic agent '''Pharmacology and Actions''' # Suppresses ventricular ectopy and increases ventricular fibrillation threshold. # Noncompetitive blocker of alpha and beta adrenergic receptors which can cause: ## Negative chronotropic effects ## Negative inotropic effects (the effect on cardiac output by the negative inotropic effect is balanced by a decrease in afterload and increase in coronary blood flow, which in turn improves cardiac performance..."

New page

'''Class'''

Antiarrhythmic agent

'''Pharmacology and Actions'''

# Suppresses ventricular ectopy and increases ventricular fibrillation threshold.
# Noncompetitive blocker of alpha and beta adrenergic receptors which can cause:
## Negative chronotropic effects
## Negative inotropic effects (the effect on cardiac output by the negative inotropic effect is balanced by a decrease in afterload and increase in coronary blood flow, which in turn improves cardiac performance [especially for patients with left ventricular failure]).
## Peripheral vasodilation (reduces afterload).
## Coronary vessel dilation
# Prolongs duration of cardiac potential and prolongs effective refractory period

'''Indications'''

# Shock resistant ventricular fibrillation or pulseless ventricular tachycardia
# Unstable ventricular tachycardia
# May be used for rate control in treatment of symptomatic atrial fibrillation or flutter when other therapies are ineffective.

'''Contraindications'''

# None in cardiac arrest with ventricular fibrillation or pulseless ventricular tachycardia
# 2<sup>nd</sup> or 3<sup>rd</sup> degree heart block in the absence of functioning pacemaker
# Marked bradycardia
# Cardiogenic shock
# Known hypersensitivity

'''Precautions'''

# Increased hypotension and bradycardia can occur when given with other beta-blockers or calcium channel blockers.
# May prolong QT interval. Do not administer with other medications that prolong QT interval (e.g., procainamide).
# Use with caution if renal failure is present, terminal elimination of amiodarone is extremely long (half-life can last up to 40 days).

'''Administration'''

# Pulseless VT / VF: 300 mg IV/IO push. Consider repeating 150 mg IV/IO push in 3-5 minutes (Maximum cumulative dose is 2.2 grams IV over 24 hours).
# Unstable VT: 150 mg slow IV/IO push over 10 minutes. Consider repeating at same dose.

'''Side Effects and Special Notes'''

# Medication must be carefully and slowly drawn from vial to avoid excess air bubbles.
# The most commonly reported side effects include hypotension, bradycardia, AV block, PEA, and hepatoxicity.

AMIODARONE (CORDARONE) - Revision history